Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07773610 Pretomanid Pulmonary Tuberculosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07773610 clinical trial report covering Pretomanid, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07772557 Serplulimab Gastroesophageal junction adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07772557 clinical trial report covering Serplulimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07774247 Tocilizumab Advanced Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07774247 clinical trial report covering Tocilizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07774754 Sintilimab MSS/pMMR/MSI-L Rectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07774754 clinical trial report covering Sintilimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07773363 Apatinib Mesylate Pancreatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07773363 clinical trial report covering Apatinib Mesylate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07773727 ARGX-121 Proteinuria Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07773727 clinical trial report covering ARGX-121, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07773935 Cycloserine Stress Disorders, Post-Traumatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07773935 clinical trial report covering Cycloserine, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07773987 Pembrolizumab Squamous Cell Carcinoma of Head and Neck Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07773987 clinical trial report covering Pembrolizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07772531 Evifacotrep Depressive Disorder, Major Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07772531 clinical trial report covering Evifacotrep, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07772245 Trastuzumab HER2-negative breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07772245 clinical trial report covering Trastuzumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07774702 Psilocybin analogs(CaaMTech) Methamphetamine abuse Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07774702 clinical trial report covering Psilocybin analogs(CaaMTech), Phase 2, endpoints, sponsor, geography, readout timing and development white space
Latest Hotspot
8 min read
NCT07776639 Docetaxel Locally Advanced Gastroesophageal Junction Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07776639 clinical trial report covering Docetaxel, Phase 2, endpoints, sponsor, geography, readout timing and development white space.